Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
PRNewswire - November 30, 2007
UPPSALA, Sweden, November 30/PRNewswire/ -- Cavidi AB, a producer of medical diagnostic products, today announced an agreement with the Clinton Foundation HIV/AIDS Initiative (CHAI). Under the agreement, Cavidi's ExaVir(TM) Load assay will be immediately available to members of CHAI's Procurement Consortium at a discounted price. With more than 70 developing countries in the consortium, the agreement is a significant step in making viral load monitoring more accessible to HIV-positive patients in the developing world.
Viral load monitoring is essential for the proper management of HIV-positive patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively to extend a patient's length and quality of life, limit the development of viral resistance and minimize waste of medication. "Viral load testing is an essential part of HIV management. As more people in the developing world gain access to ARVs, it's important that access to viral load testing keeps pace," said Cavidi CEO Martyn Eales. "It's Cavidi's goal to make monitoring more accessible in all countries. I'm very pleased with our partnership with President Clinton's Foundation because it brings us closer to reaching that goal."
Although viral load monitoring has been a standard part of treatment in developed countries, it has been considered impractical for use in developing nations where HIV infection is most widespread. That is because traditional viral load tests are expensive and require technically advanced laboratory facilities. ExaVir Load is the first HIV viral load test designed to overcome these obstacles. Several independent studies have shown the assay to be as accurate and reliable as any other commercially available test, with the added benefit of being able to detect all known subtypes of HIV. This is particularly important in regions like sub-Saharan Africa where different HIV subtypes are common.
"We face a global HIV/AIDS emergency and laboratory tests are a vital component of HIV/AIDS care and treatment," said Deepak Verma, CEO of CHAI. "The success of treatment programs is dependent not only on the ability to diagnose and qualify HIV-positive patients for therapy, but also to monitor treatment efficacy and safety and to manage disease treatment. We are pleased to work with Cavidi and commend them for helping to make HIV viral load tests available at lower cost to members of our Procurement Consortium."
About Cavidi AB
Cavidi AB was founded by leading virologists at Uppsala University in Sweden in 1984. The company's mission is to make medical diagnostics more accessible in those parts of the world where resources and infrastructure are limited. Their products include ExaVir Load and ExaVir Drug, which are used in HIV management. For press photos and more information, please visit, http://www.cavidi.com
About Clinton Foundation HIV/AIDS Initiative (CHAI)
Since 2002, CHAI has been assisting countries in implementing large-scale, integrated HIV/AIDS care and treatment programs. It partners with 28 countries in Africa, the Caribbean and Asia. Individual governments take the lead and CHAI provides technical assistance, mobilizes human and financial resources, and facilitates the sharing of best practices across projects. CHAI also provides access to reduced prices for HIV/AIDS drugs and diagnostics to more than 70 countries.
For more information, please visit: http://www.clintonfoundation.org
For further information and interview requests please contact:
Kajsa Lowenhielm, Information Manager, Cavidi AB, Mobile: +46-709-42-90-50, kajsa@cavidi.se
Source: Cavidi AB
071130
PR0711D4
Copyright © 2007 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .